|
1
|
Writing Group Members. Mozaffarian D,
Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de
Ferranti S, Després JP, et al: Heart disease and stroke
statistics-2016 update: A report from the American heart
association. Circulation. 133:e38–360. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yellon DM and Hausenloy DJ: Myocardial
reperfusion injury. N Engl J Med. 357:1121–1135. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Javadov S, Jang S, Parodi-Rullan R,
Khuchua Z and Kuznetsov AV: Mitochondrial permeability transition
in cardiac ischemia-reperfusion: Whether cyclophilin D is a viable
target for cardioprotection? Cell Mol Life Sci. 74:2795–2813.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jiang B, Liu Y, Liang P, Li Y, Liu Z, Tong
Z, Lv Q, Liu M and Xiao X: MicroRNA-126a-5p enhances myocardial
ischemia-reperfusion injury through suppressing Hspb8 expression.
Oncotarget. 8:94172–94187. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Portal L, Martin V, Assaly R, d'Anglemont
de Tassigny A, Michineau S, Berdeaux A, Ghaleh B and Pons S: A
model of hypoxia-reoxygenation on isolated adult mouse
cardiomyocytes: Characterization, comparison with
ischemia-reperfusion, and application to the cardioprotective
effect of regular treadmill exercise. J Cardiovasc Pharmacol Ther.
18:367–375. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang X, Du Q, Yang Y, Wang J, Dou S, Liu
C and Duan J: The protective effect of Luteolin on myocardial
ischemia/reperfusion (I/R) injury through TLR4/NF-kappaB/NLRP3
inflammasome pathway. Biomed Pharmacother. 91:1042–1052.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Imarisio C, Alchera E, Bangalore Revanna
C, Valente G, Follenzi A, Trisolini E, Boldorini R and Carini R:
Oxidative and ER stress-dependent ASK1 activation in steatotic
hepatocytes and Kupffer cells sensitizes mice fatty liver to
ischemia/reperfusion injury. Free Radic Biol Med. 112:141–148.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Belleville JP, Ward DS, Bloor BC and Maze
M: Effects of intravenous dexmedetomidine in humans. I. Sedation,
ventilation, and metabolic rate. Anesthesiology. 77:1125–1133.
1992.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Weerink MAS, Struys MMRF, Hannivoort LN,
Barends CRM, Absalom AR and Colin P: Clinical Pharmacokinetics and
Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet.
56:893–913. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cai Y, Xu H, Yan J, Zhang L and Lu Y:
Molecular targets and mechanism of action of dexmedetomidine in
treatment of ischemia/reperfusion injury. Mol Med Rep. 9:1542–1550.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen Z, Ding T and Ma CG: Dexmedetomidine
(DEX) protects against hepatic ischemia/reperfusion (I/R) injury by
suppressing inflammation and oxidative stress in NLRC5 deficient
mice. Biochem Biophys Res Commun. 493:1143–1150. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang L, Liu H, Zhang L, Wang G, Zhang M
and Yu Y: Neuroprotection of dexmedetomidine against cerebral
ischemia-reperfusion injury in rats: Involved in inhibition of
NF-κB and inflammation response. Biomol Ther (Seoul). 25:383–389.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen J, Huang ZP, Seok HY, Ding J, Kataoka
M, Zhang Z, Hu X, Wang G, Lin Z, Wang S, et al: mir-17-92 cluster
is required for and sufficient to induce cardiomyocyte
proliferation in postnatal and adult hearts. Circ Res.
112:1557–1566. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
de Pontual L, Yao E, Callier P, Faivre L,
Drouin V, Cariou S, Van Haeringen A, Geneviève D, Goldenberg A,
Oufadem M, et al: Germline deletion of the miR-17~92 cluster causes
skeletal and growth defects in humans. Nat Genet. 43:1026–1030.
2011.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Mendell JT: miRiad roles for the miR-17-92
cluster in development and disease. Cell. 133:217–222.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261.
2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yan H, Song K and Zhang G: MicroRNA-17-3p
promotes keratinocyte cells growth and metastasis via targeting
MYOT and regulating Notch1/NF-κB pathways. Die Pharmazie.
72:543–549. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li C, Lu J and Zhang B: Development of a
novel chronic intermittent hypoxia chamber. Sleep Breath.
16:177–179. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rakoff-Nahoum S and Medzhitov R: Toll-like
receptors and cancer. Nat Rev Cancer. 9:57–63. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Huebener P and Schwabe RF: Regulation of
wound healing and organ fibrosis by toll-like receptors. Biochim
Biophys Acta. 1832:1005–1017. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lin Q, Li M, Fang D, Fang J and Su SB: The
essential roles of Toll-like receptor signaling pathways in sterile
inflammatory diseases. Int Immunopharmacol. 11:1422–1432.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kuno M, Nemoto K, Ninomiya N, Inagaki E,
Kubota M, Matsumoto T and Yokota H: The novel selective toll-like
receptor 4 signal transduction inhibitor tak-242 prevents
endotoxaemia in conscious Guinea-pigs. Clin Exp Pharmacol Physiol.
36:589–593. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sha T, Sunamoto M, Kitazaki T, Sato J, Ii
M and Iizawa Y: Therapeutic effects of TAK-242, a novel selective
Toll-like receptor 4 signal transduction inhibitor, in mouse
endotoxin shock model. Eur J Pharmacol. 571:231–239.
2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen Z, Qiu PY and Ma CG: Dexmedetomidine
preconditioning protects against retinal ischemia/reperfusion
injury and inhibits inflammation response via toll-like receptor 4
(TLR4) pathway. Biomed Pharmacother. 93:1018–1024. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Simon D, Derer A, Andes FT, Lezuo P, Bozec
A, Schett G, Herrmann M and Harre U: Galectin-3 as a novel
regulator of osteoblast-osteoclast interaction and bone
homeostasis. Bone. 105:35–41. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
de Boer RA, Voors AA, Muntendam P, van
Gilst WH and van Veldhuisen DJ: Galectin-3: A novel mediator of
heart failure development and progression. Eur J Heart Fail.
11:811–817. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marques-Fernandez F, Planells-Ferrer L,
Gozzelino R, Galenkamp KM, Reix S, Llecha-Cano N, Lopez-Soriano J,
Yuste VJ, Moubarak RS and Comella JX: TNFα induces survival through
the FLIP-L-dependent activation of the MAPK/ERK pathway. Cell Death
Dis. 4(e493)2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Crusz SM and Balkwill FR: Inflammation and
cancer: Advances and new agents. Nat Rev Clin Oncol. 12:584–596.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tanaka T, Narazaki M and Kishimoto T: IL-6
in inflammation, immunity, and disease. Cold Spring Harb Perspect
Biol. 6(a016295)2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Striz I: Cytokines of the IL-1 family:
Recognized targets in chronic inflammation underrated in organ
transplantations. Clin Sci (Lond). 131:2241–2256. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang YX, Ji ML, Jiang CY and Qian ZB:
Upregulation of ICAM-1 and IL-1beta protein expression promotes
lung injury in chronic obstructive pulmonary disease. Genet Mol
Res. 15:2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang YC, Ye H, Zeng Z, Chin YE, Huang YN
and Fu GH: The NF-kappaB p65/miR-23a-27a-24 cluster is a target for
leukemia treatment. Oncotarget. 6:33554–33567. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn
B and Prabhu SD: Cardiomyocyte NF-κB p65 promotes adverse
remodelling, apoptosis, and endoplasmic reticulum stress in heart
failure. Cardiovasc Res. 89:129–138. 2011.PubMed/NCBI View Article : Google Scholar
|
